Volume 6, Issue 7, Pages 601-609 (July 2019) Optimal dose of selective serotonin reuptake inhibitors, venlafaxine, and mirtazapine in major depression: a systematic review and dose-response meta-analysis Prof Toshi A Furukawa, MD, Prof Andrea Cipriani, MD, Prof Philip J Cowen, FRCPsych, Stefan Leucht, MD, Prof Matthias Egger, MD, Georgia Salanti, PhD The Lancet Psychiatry Volume 6, Issue 7, Pages 601-609 (July 2019) DOI: 10.1016/S2215-0366(19)30217-2 Copyright © 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license Terms and Conditions
Figure 1 Study selection The Lancet Psychiatry 2019 6, 601-609DOI: (10.1016/S2215-0366(19)30217-2) Copyright © 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license Terms and Conditions
Figure 2 Dose-outcome relationships for selective serotonin reuptake inhibitors (99 treatment groups) RR=risk ratio. Each tick on the x-axis represents the dose examined in a treatment group. The dotted lines represent 95% CIs. The Lancet Psychiatry 2019 6, 601-609DOI: (10.1016/S2215-0366(19)30217-2) Copyright © 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license Terms and Conditions
Figure 3 Dose-outcome relationships for venlafaxine (16 treatment groups) RR=risk ratio. Each tick on the x-axis represents the dose examined in a treatment group. The dotted lines represent 95% CIs. The Lancet Psychiatry 2019 6, 601-609DOI: (10.1016/S2215-0366(19)30217-2) Copyright © 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license Terms and Conditions
Figure 4 Dose-outcome relationships for mirtazapine (11 treatment groups) RR=risk ratio. Each tick on the x-axis represents the dose examined in a treatment group. The dotted lines represent 95% CIs. The Lancet Psychiatry 2019 6, 601-609DOI: (10.1016/S2215-0366(19)30217-2) Copyright © 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license Terms and Conditions